Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis.
Objective:
The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis.
Methods:
Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A “treatment change” was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class.
Results:
Seventy-seven treatment changes were identified. On average, 1 treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control.
Conclusions:
Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
ParisiRSymmonsDPGriffithsCEAshcroftDM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.
2.
MenterAGottliebAFeldmanSR. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
3.
BonafedeMFoxKMWatsonCPrincicNGandraSR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664-674.
4.
ChastekBFoxKMWatsonCKricorianGGandraSR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24(1):25-33.
5.
SvedbomADalenJMamoloCCappelleriJCPeterssonIFStahleM. Treatment patterns with topicals, traditional systemics and biologics in psoriasis—a Swedish database analysis. J Eur Acad Dermatol Venereol. 2015;29(2):215-223.
6.
WoldemedhinBWabeNT. The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in southern Ethiopia. N Am J Med Sci. 2012;4(1):19-23.
7.
Engel-NitzNMDarkowTLauH. Antihypertensive medication changes and blood pressure goal achievement in a managed care population. J Hum Hypertens. 2010;24(10):659-668.
8.
TinazziMAbbruzzeseGAntoniniA. Reasons driving treatment modification in Parkinson’s disease: results from the cross-sectional phase of the REASON study. Parkinsonism Relat Disord. 2013;19(12):1130-1135.
9.
ChristeVWaeberGVollenweiderPMarques-VidalP. Antihypertensive drug treatment changes in the general population: the CoLaus study. BMC Pharmacol Toxicol. 2014;15(1):20.
10.
LevinAAGottliebABAuSC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848-853.
11.
DueEBlombergMSkovLZachariaeC. Discontinuation of methotrexate in psoriasis. Acta Derm Venereol. 2012;92(4):353-354.
12.
GniadeckiRBangBBryldLEIversenLLastheinSSkovL. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244-252.
13.
GniadeckiRKragballeKDamTNSkovL. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091-1096.
14.
GulliverWGregoryVKhalilSMallyaU. Biologic switching and discontinuation patterns in patients with moderate to severe plaque psoriasis. Poster presented at: 23rd EADV Congress; October 8-12, 2014; Amsterdam, the Netherlands.
15.
YeungHWanJVan VoorheesAS. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64-72.
16.
OrmerodAD. Switching biologics for psoriasis. Br J Dermatol. 2010;163(4):667-669.
17.
Van LumigPPLecluseLLDriessenRJ. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol. 2010;163(4):838-846.
18.
DownsAM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Br J Dermatol. 2010;163(2):433-434.
19.
PiasericoSCazzanigaSChimentiS. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol. 2014;70(2):257-262.
20.
FeldmanSRFleischerABJrReboussinDM. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564-569.
21.
PearceDJNelsonAAFleischerABBalkrishnanRFeldmanSR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006;17(1):29-37.
22.
FowlerJFDuhMSRovbaL. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772-780.
23.
KimballABGielerULinderDSampognaFWarrenRBAugustinM. Psoriasis: is the impairment to a patient’s life cumulative?J Eur Acad Dermatol Venereol. 2010;24(9):989-1004.
24.
MatteiPLCoreyKCKimballAB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol. 2013;44:82-90.
